Docetaxel in Advanced and Castration Resistant Prostate Cancer
Petrylak D, Hafez N. Docetaxel in Advanced and Castration Resistant Prostate Cancer. 2016, 77-92. DOI: 10.1007/978-3-319-31341-2_6.Peer-Reviewed Original ResearchResistant prostate cancerProstate cancerMetastatic castrate-resistant prostate cancerCastrate-resistant metastatic diseaseMetastatic castrate-resistant diseaseCastration-resistant prostate cancerCastrate-resistant prostate cancerResistant metastatic diseaseCastrate-resistant diseasePrimary chemotherapeutic agentStandard of careDocetaxel useTaxane cabazitaxelMetastatic diseaseDocetaxel efficacyRandomized trialsResistant diseaseLocal diseaseSuperior survivalDocetaxelChemotherapeutic agentsCancerDiseaseCorticosteroidsCabazitaxelThe impact of androgen deprivation and pelvic radiation on the development of bladder cancer.
Hafez N, Wang R, Hurwitz M, Ma X, Petrylak D. The impact of androgen deprivation and pelvic radiation on the development of bladder cancer. Journal Of Clinical Oncology 2016, 34: 439-439. DOI: 10.1200/jco.2016.34.2_suppl.439.Peer-Reviewed Original ResearchAndrogen deprivation therapyUrothelial bladder cancerProstate cancer patientsSecondary bladder cancerBladder cancerCancer patientsRadiation therapyAndrogen deprivationProstate cancerRecurrent urothelial bladder cancerElderly prostate cancer patientsCox proportional modelingRetrospective cohort studyKaplan-Meier analysisSEER-Medicare databaseSimilar patient populationsProstate cancer treatmentPrimary prostate cancerDeprivation therapyMedian followPelvic radiationCohort studyMale predilectionProportional modelingPatient population